- Home
- CVBF vs ARQT Comparison
CVBF vs ARQT Comparison
Compare CVBF & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CVBF | ARQT |
|---|---|---|
| Founded | 1974 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CVBF | ARQT |
|---|---|---|
| Price | $20.52 | $23.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $24.50 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 1.9M | 920.2K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.95% | N/A |
| EPS Growth | 5.56 | ★ 88.79 |
| EPS | ★ 1.52 | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $21.47 | $34.85 |
| Revenue Next Year | $15.21 | $29.39 |
| P/E Ratio | $13.26 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $17.95 | $12.42 |
| 52 Week High | $21.48 | $31.77 |
Technical Indicators
Market Signals| Indicator | CVBF | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 48.63 |
| Support Level | $19.84 | $22.56 |
| Resistance Level | $20.53 | $23.46 |
| Average True Range (ATR) | 0.48 | 0.89 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 48.99 | 48.31 |
Price Performance
Historical ComparisonAbout CVBF CVB Financial Corporation
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit. It is a community bank with one reportable operating segment.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.